


JAN 24 2002


Approved for use through 10/31/2002. OMB 0547-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;"><i>(to be used for all correspondence after initial filing)</i></p>		Application Number	09/990,080
		Filing Date	21 November 2001
		First Named Inventor	Gregg B. Morin
		Group Art Unit	1632
		Examiner Name	To be determined
Total Number of Pages in This Submission		Attorney Docket Number	018/258C

ENCLOSURES		(check all that apply)	
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group	PTO Form 1449; References (28)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer		
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund		
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____		
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application			
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53			
Remarks			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	J. Michael Schiff, Registration No. 40,253
Signature	
Date	January 18, 2002

CERTIFICATE OF HAND DELIVERY			
I hereby certify that this correspondence is being delivered by hand to the U.S. Patent Office in accordance with 37 CFR 1.6(b), addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on this date: 11/23/02			
Typed or printed name	Shari Hall White		
Signature		Date	11/23/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PATENT

Dw
2/5/02

CERTIFICATE OF HAND DELIVERY

I hereby certify that this correspondence is being delivered by hand to the U.S. Patent Office in accordance with 37 CFR § 1.6(b), addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated.

Gregg B. Morin
Name

1/23/02
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Gregg B. Morin

Art Unit: 1632

Serial No.: 09/990,080

Examiner: TBD

Filing Date: 21 November 2001

For: Human Telomerase Catalytic Subunit
Variants

RECEIVED
PTO CENTER 1600/2900
02 JAN 23 PM 2:46

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

It is believed that no fee is required for submission of this Statement, which is filed before the first Office Action on the merits of the application. Nevertheless, should a fee be required for consideration of this Statement and the listed information, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 07-1139, referencing the attorney Docket Number indicated above.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. Michael Schiff', with a long horizontal stroke extending to the right.

J. Michael Schiff
Registration No. 40,253

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7715
Fax: (650) 473-8654

DATE: January 18, 2002

Form 1449 (modified)	Docket: 018/258C	U.S.S.N. 09/990,080
Information Disclosure Statement By Applicant	Title: Human Telomerase Catalytic Subunit Variants Inventors: Gregg B. Morin	
(Use Several Sheets if Necessary)	Filing Date: 21 November 2001	Group: 1632

U.S. Patent Documents

Examiner Initial	Ref.	Patent No.	Filing Date	Issue Date	Class/ Subclass	Inventors:	Title:
	A	6,261,556	Oct 18/99	Jul 17/01	424/94.5	Weinrich SL et al.	Purified Telomerase
	B	6,261,836	May 9/97	Jul 17/01	435/325	Cech TR et al.	Telomerase

Foreign Patent or Published Foreign Patent Application

Examiner Initial	Ref.	Document No.	Publ. Date	Jurisdiction	Title:	Translation	
						Yes	No
	C	WO 98/07838	Feb 26/98	PCT	Higher Animal Telomerase Protein and Gene Encoding the Same; With Derwent Summary in English	Summary	
	D	WO 98/21343	May 22/98	PCT	Genes Encoding Telomerase Proteins		
	E	WO 98/37181	Aug 28/98	PCT	Telomerase Catalytic Subunit Gene and Encoded Protein		
	F	WO 99/01560	Jan 14/99	PCT	Vertebrate Telomerase Genes and Proteins and Uses Thereof		

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source
	G	Bachand et al., Functional Regions of Human Telomerase Reverse Transcriptase and Human Telomerase RNA Required for Telomerase Activity and RNA-Protein Interactions, Mol. and Cellular Biol. 21:1888 (2001)
	H	Bodnar et al., Extension of Life-span by Induction of Telomerase into Normal Human Cells, Science 279:349 (1998)
	I	Bryan et al., A Mutant of <i>Tetrahymena</i> Telomerase Reverse Transcriptase with Increased Processivity, J. Biol. Chem. 275:24199 (2000)
	J	Bryan et al., Telomerase RNA Bound by Protein Notifs Specific to Telomerase Reverse Transcriptase, Molecular Cell 6:493 (2000)
	K	Bryan et al., Telomerase reverse transcriptase genes identified in <i>Tetrahymena thermophila</i> and <i>Oxytricha trifallax</i> , Proc. Natl. Acad. Sci. USA 95:8479 (1998)
	L	Colgin et al., The hTERTapha splice variant is a dominant negative inhibitor of telomerase activity, Neoplasia 2:426 (2000)
	M	Farmery et al., Major Histocompatibility Class I Folding, Assembly, and Degradation: A Paradigm for Two-Stage Quality Control in the Endoplasmic Reticulum, Progress in Nucleic Acid Res. 67:235 (2001)
	N	Freidman et al., Essential functions of amino-terminal domains in the yeast telomerase catalytic subunit revealed by selection for variable mutants, Genes & Dev. 13:2863 (1999)
	O	Haering et al., Analysis of telomerase catalytic subunit mutants <i>in vivo</i> and <i>in vitro</i> in <i>Schizosaccharomyces pombe</i> , PNAS 97:6367 (2000)
	P	Hahn et al., Inhibition of telomerase limits the growth of human cancer cells, Nature Medicine 5:1164 (1999)
	Q	Harrington et al., Human telomerase contains evolutionarily conserved catalytic and structural subunits, Genes Dev. 11:3109 (1997)
	R	Kilian et al., Isolation of a Candidate Human Telomerase Catalytic Subunit Gene, Which Reveals Complex Splicing Patterns in Different Cell Types, Hum. Mol. Genet. 6:2011 (1997)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449 (modified)	Docket: 018/258C	U.S.S.N. 09/990,080
Information Disclosure Statement By Applicant	Title: Human Telomerase Catalytic Subunit Variants Inventors: Gregg B. Morin	
(Use Several Sheets if Necessary)	Filing Date: 21 November 2001	Group: 1632

Other Documents

Examiner Initial	Ref.	Author, Title, Date, Source
	S	Lai et al., RNA Binding Domain of Telomerase Reverse Transcriptase, Mol. and Cellular Biol. 21:990 (2000)
	T	Lingner et al., Reverse Transcriptase Motifs in the Catalytic Subunit of Telomerase, Science 276:561 (1997)
	U	Morin, The Implications of Telomerase Biochemistry for Human Disease, Eur. J. Biol. Chem. 33:750(1998)
	V	Myerson et al., hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization, Cell 90:785 (1997)
	W	Nakamura et al., Telomerase Catalytic Subunit Homologs from Fission Yeast and Human, Science 277:955 (1997)
	X	Perez et al., Human formyl peptide receptor ligand binding domain(s). Studies using an improved mutagenesis/expression vector reveal a novel mechanism for the regulation of receptor occupancy, J. Biol. Chem. 269:22485 (1994)
	Y	Solheim et al., Class I MHC molecules: assembly and antigen presentation, Immun. Reviews 172:11 (1999)
	Z	Weinrich et al., Reconstitution of Human Telomerase with the Template RNA Component hTR and the Catalytic Protein Subunit hTRT, Nat. Genet. 17:498 (1997)
	AA	Xia et al., Identification of Functionally Important Domains in the N-Terminal Region of Telomerase Reverse Transcriptase, Mol. and Cellular Biol. 20:5196 (2000)
	AB	Zakharova et al., Structural Constraints in the HIV-1 Reverse Transcriptase-Primer/Template Complex for the Initiation of DNA Synthesis from Primer tRNA ^{Lys3} , Biochem. 37:13343 (1998)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**
PTO-1449 — Page 2